There will always be anecdotal information about a certain drug used off-label having shown benefits to a limited cohort under a defined set of circumstances. That is the case with HCQ and several other drugs used to treat Covid 19 patients, both prohylatically, after exposure and after symptomatic onset. However, the advocates of these drugs have yet to organize and/or present any double blind, peer-reviewed studies affirming in these results more broadly in larger scale tests. Until they do so, doctors are free to use these drugs in individual cases if they believe they will be effective for treating their patients but there is ZERO basis to recommend them to the general population as an “approved” therapy.
